[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  FinanceFrontierAI πΊπΈ [@FinFrontierAI](/creator/twitter/FinFrontierAI) on x 4294 followers Created: 2025-02-07 16:16:54 UTC π Deep Dive into $ETST Explosive Growth & Catalystsπ Massive Revenue Growth: β’ Q2 Revenue: $8.5M vs. $1.9M YoY (+695%) β’ 6-Month Revenue: $17.08M vs. $2.1M YoY (+695%) β’ Gross Margin: XX% (Improving Profitability) π° Float Reduction via Buybacks: β’ Shares Outstanding: 315M β 297M (-5.53%) β’ 17.4M shares repurchased, reducing dilution risk β’ Buyback program still active through 2025π₯ Expanding into High-Growth Sectors: Acquisitions Strengthening Market Position β’ Las Villas Healthcare & Doconsultations β Telemedicine & Pharma β’ Magnefuse & Alicat β Medical Innovations & Equipment β’ Zoolzy Pet Pharmacy Launched (Tapping into pet health market) π Next Catalyst: EPS Report β Will it turn positive? β’ Net Income Last Quarter: $798K β’ $1.53M in Cash vs. $697K prior quarter (Strong liquidity) β’ Executive compensation tied to revenue growth β Incentive to scale βοΈ Why $ETST Looks Undervalued: β’ Current Price: $XXXXXX β’ Target Price: $XXXX β’ Upside Potential: +179% β’ Risk-Reward Ratio: 11:1 π Big Growth, Low Valuation β A Hidden Gem? π Podcast link in bio. XX engagements  **Related Topics** [stocks](/topic/stocks) [$21m](/topic/$21m) [$1708m](/topic/$1708m) [$19m](/topic/$19m) [$85m](/topic/$85m) [quarterly earnings](/topic/quarterly-earnings) [$etst](/topic/$etst) [Post Link](https://x.com/FinFrontierAI/status/1887898339137454128)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
FinanceFrontierAI πΊπΈ @FinFrontierAI on x 4294 followers
Created: 2025-02-07 16:16:54 UTC
π Deep Dive into $ETST Explosive Growth & Catalystsπ
Massive Revenue Growth: β’ Q2 Revenue: $8.5M vs. $1.9M YoY (+695%) β’ 6-Month Revenue: $17.08M vs. $2.1M YoY (+695%) β’ Gross Margin: XX% (Improving Profitability)
π° Float Reduction via Buybacks: β’ Shares Outstanding: 315M β 297M (-5.53%) β’ 17.4M shares repurchased, reducing dilution risk β’ Buyback program still active through 2025π₯
Expanding into High-Growth Sectors:
Acquisitions Strengthening Market Position β’ Las Villas Healthcare & Doconsultations β Telemedicine & Pharma β’ Magnefuse & Alicat β Medical Innovations & Equipment β’ Zoolzy Pet Pharmacy Launched (Tapping into pet health market)
π Next Catalyst: EPS Report β Will it turn positive? β’ Net Income Last Quarter: $798K β’ $1.53M in Cash vs. $697K prior quarter (Strong liquidity) β’ Executive compensation tied to revenue growth β Incentive to scale
βοΈ Why $ETST Looks Undervalued: β’ Current Price: $XXXXXX β’ Target Price: $XXXX β’ Upside Potential: +179% β’ Risk-Reward Ratio: 11:1
π Big Growth, Low Valuation β A Hidden Gem?
π Podcast link in bio.
XX engagements
Related Topics stocks $21m $1708m $19m $85m quarterly earnings $etst
/post/tweet::1887898339137454128